The preclinical finding
Following induced myocardial infarction in rodents, administration of thymosin beta-4 was associated with improved cardiac function and reduced infarct scar size relative to controls. Histology suggested the effect came from improved survival of existing cardiac cells and reduced fibrotic replacement, rather than from regeneration of new heart muscle.
The mechanism proposed was consistent with thymosin beta-4's known role in actin regulation and cell migration — cells surviving the ischaemic insult more effectively and migrating to damaged regions.
This was a strong and well-publicised finding, and it is one of the reasons thymosin beta-4 has such a reputation in the recovery space.
What happened in humans
Clinical development followed, and this is where the story becomes more instructive than the finding.
The human trials used the full-length protein, delivered under controlled clinical conditions, in patients with recent myocardial infarction. Results were mixed. Some signals favoured treatment; several endpoints showed no significant difference from placebo.
The important detail for anyone reading this library: the trials did not test TB-500. They tested the parent protein, administered by clinicians at doses and via routes that were never intended to translate into a self-administered fragment protocol. The community compound and the studied intervention are related molecules, not the same intervention.
Why the fragment is used instead
TB-500 is a shortened fragment of thymosin beta-4, chosen because it is more stable and easier to synthesise. The assumption is that the active region of the protein is retained in the fragment. That assumption is reasonable — the actin-binding region is indeed within the fragment — but it is an assumption. Whether the fragment reproduces the full protein's effects in a whole organism has not been established.
The safety signal worth noting
Thymosin beta-4 has documented roles in cell migration and proliferation and has been found upregulated in several tumour types. It is not a compound with a clean mechanistic profile in oncology contexts. That is a legitimate reason for caution in anyone with a cancer history, and it is not a claim that the peptide causes cancer.
How to read the claim
You will encounter TB-500 described as "shown to repair the heart". A more accurate statement is that the full-length parent protein improved cardiac outcomes in animal models and produced mixed results in human trials of a different formulation.
That is still a more interesting evidence base than most compounds here have. It is simply not the same claim.